|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
價值評估 |
盈利(現時/預測)
-315.39/-0.14
|
企業價值
2.96M
|
資產負債 |
每股賬面淨值
1.70
|
現金流量 |
現金流量率
--
|
損益表 |
收益
5.00K
|
每股收益
1.83
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘:2025/01/11 11:27 EST
同行比較之報價最少15分鐘延遲
業務概覽
|
|||
Alaunos Therapeutics Inc is a clinical-stage cellular immuno-oncology company dedicated to the treatment of solid tumors through adoptive TCR-T cell therapy. It strikes cancer at its core by engineering cell therapies that target Neoantigens arising from genomic mutations. |